AcelRx Pharmaceuticals, Inc. (ACRX)
(Delayed Data from NSDQ)
$3.66 USD
+0.10 (2.81%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.66 USD
+0.10 (2.81%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys
by Tirthankar Chakraborty
After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.
All You Need to Know About AcelRx Pharmaceuticals (ACRX) Rating Upgrade to Buy
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q4 Earnings Expected to Decline
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.
AcelRx Pharmaceuticals (ACRX) Stock Moves -1.14%: What You Should Know
by Zacks Equity Research
In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.73, marking a -1.14% move from the previous day.
AcelRx Pharmaceuticals (ACRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.91, marking a -0.78% move from the previous day.
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
by Zacks Equity Research
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
by Zacks Equity Research
The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
by Zacks Equity Research
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
Have Faith in Rising P/E: Play 5 Top-Ranked Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for January 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 3rd
Jazz Enrolls First Patient in Phase II/III Leukemia Study
by Zacks Equity Research
Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
by Zacks Equity Research
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AcelRx Pharmaceuticals, Inc. (ACRX) has been struggling lately, but the selling pressure may be coming to an end soon.
AcelRx Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
AcelRx Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 30.43% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 30.43% and -39.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AcelRx Pharmaceuticals (ACRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for AcelRx (ACRX) This Earnings Season?
by Zacks Equity Research
AcelRx (ACRX) will provide updates on the launch and sales of Dsuvia when it releases second-quarter 2019 results.
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
by Zacks Equity Research
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.